No drug specifically targets mGPX4, but the feasibility of developing general GPX4 inhibitors for cancer therapy has been verified with many cancer models, including melanoma [133], renal cell carcinoma [134], small cell lung cancer [135], breast cancer [136–139], and other models [20, 140]. The gene discussed is GPX4; the disease is cancer.